TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Time to complete the time trial
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscular endurance increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: heart failure hospitalization or cardiovascular mortality
Endpoint domain: Mortality/survival
Primary endpoint: gain in diabetes knowledge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: drowsiness after sedation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: require additional analgesic
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hemodynamic instability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improvement in tardive dyskinesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Improvement in parkinsonian symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Discontinuation due to nausea and/or vomiting
Endpoint domain: Adverse events/effects
Primary endpoint: Time to discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: body dissatisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: self-efficacy
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: changes in proteinuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Average life-span
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of patients died within 6 months
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of patients died within 1 year
Endpoint domain: Mortality/survival
Primary endpoint: Cell numbers of bifidobacteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cell numbers of B fragilis group
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ratio of cell numbers of B fragilis group to bifidobacteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total misoprostol use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total analgesic use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in systolic blood pressure (SBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of patients becoming asymptomatic
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients developing syncope
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decrease in body mass index (BMI) z‐score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C reactive protein (CRP) value >20 mg/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Findings on ear examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parents' assessment that the child has a bacterial infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CRQ dyspnoea score change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wexner score for severity assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FIQL for evaluating quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: severe anemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: leukopenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: neutropenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Dysphagia rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Patient satisfaction with operative result
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reflux control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Median survival rate
Endpoint domain: Mortality/survival
Primary endpoint: Improvement of clinical symptoms and QOL
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Incidence rate and degree of CT toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Inhibition of AI induced vasoconstriction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 25OHD levels at 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants achieving 25OHD sufficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: endodontic treatment time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: one-leg standing time with eyes open
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of people who fell during the 6 months
Endpoint domain: Adverse events/effects
Primary endpoint: improvement in independence in daily living
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Total retinal thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total nerve fiber layer thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of type 1 diabetes by age 8
Endpoint domain: Mortality/survival
Primary endpoint: Localization of nodule
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cases of pneumothorax
Endpoint domain: Adverse events/effects
Primary endpoint: insulin sensitivity improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: lipid pattern improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Threshold ROP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ophthalmological outcomes
Primary endpoint: Efficacy for treating positive symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical responder criteria fulfillment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy for treating negative symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Opioid stigma perceptions
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: sfCOMP‐Bio concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Primary events observed
Endpoint domain: Mortality/survival
Primary endpoint: PCO severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: drinks per drinking day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: final remission rate
Endpoint domain: Mortality/survival
Primary endpoint: cognitive side effects
Endpoint domain: Adverse events/effects
Primary endpoint: memory deficits severity
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Subjective units of distress (SUD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bi‐compartmental pharmacokinetic parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Deviation (MD) improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of PUFAs in the prodromal phase of FEP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Caregiver's burden
Endpoint domain: Life impact
Endpoint subdomain: Societal/carer burden
Primary endpoint: Serum adiponectin concentration increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Platelet activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Graft function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Physical Frailty (PF) status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Testosterone concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Dehydroepiandrosterone (DHEA) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: sleep hygiene
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: insomnia severity
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: stress symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Hearing recovery rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tongue Coating Index (TCI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: File tip location accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with HbA(1c) at target
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Progression to permanent insulin use
Endpoint domain: Adverse events/effects
Primary endpoint: Peak expiratory flow rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Maximum voluntary ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: ALT levels post-operation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver biochemistry outcomes
Primary endpoint: hyperactive behaviour
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumour delineation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CNR (Contrast-to-Noise Ratio)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: complete STR achievement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 6-month major adverse cardiac event-free survival
Endpoint domain: Mortality/survival
Primary endpoint: leg jerking
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: emotional response to a pleasant stimulus
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: standardized patient examination skills
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Circulating irisin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptance rate of recommendations
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: anti-HIV activity in CVL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Anaesthetic medications used
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Two-year estimated mortality rates
Endpoint domain: Mortality/survival
Primary endpoint: HIV‐1‐free survival at 2 years
Endpoint domain: Mortality/survival
Primary endpoint: Maximum ventricular rate during atrial fibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Duration of atrial fibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Feeling of close-to-win
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: PEP rate
Endpoint domain: Adverse events/effects
Primary endpoint: median period until dislodgement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: plasma concentrations of oleic and α‐linolenic acids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: incidence, reversion and prevalence of MetS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Retrieval rate of RBCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: [Ca(2+)]i in RBCs after washing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Abnormal RBCs and fragments of RBCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean serum tolterodine concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean MR of debrisoquine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean MR of omeprazole hydroxylation and sulphoxidation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: trembling velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: trembling frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in Strength and Difficulties Questionnaire scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reduction in total sleeping problems
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Peak oxygen consumption (V˙O2peak)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Acute rectal toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Acute urinary toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Biochemical relapse
Endpoint domain: Mortality/survival
Primary endpoint: Time to run/walk 30 feet
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of immunotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Results of nasal provocation test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Results of acoustic rhinometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of bacteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Coordination ability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sway area of the center of pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum knee isometric force
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Upper limb muscle endurance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Reduction in duration of 'on' periods with LID
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal LID score at rest during levodopa challenge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: articular index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: morning stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of recovery (QoR-15 score)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Pain levels
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: pentosidine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: perceived intensity of heat pain stimuli
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in serum sodium concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall 5-year survival
Endpoint domain: Mortality/survival
Primary endpoint: Disease-free survival at 5 years
Endpoint domain: Mortality/survival
Primary endpoint: Local recurrence rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of sinusitis recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fear of Relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in severity of negative symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life assessment (physical component scale)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Quality of life assessment (psychological well-being scale)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Induction to vaginal delivery time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of hyperstimulation
Endpoint domain: Adverse events/effects
Primary endpoint: Maternal satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of donor cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Complete donor chimera status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Bone marrow relapse
Endpoint domain: Adverse events/effects
Primary endpoint: Pain in eyes
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Epiphora
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Epithelial defect size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: students' overall object control skills
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: teacher-rated peer leadership
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Calorie consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of In-Stent Aneurysm (ISA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mortality at day 28
Endpoint domain: Mortality/survival
Primary endpoint: Presence and use of assistive devices
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Reduction in ADHD symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in individually defined behaviour problems
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in comorbid symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean utility for flash monitoring
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean utility for conventional monitoring
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: proteomic CAD score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of End-Stage Renal Disease (ESRD)
Endpoint domain: Mortality/survival
Primary endpoint: Muscle cramping after L-carnitine supplementation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intradialytic hypotension response to L-carnitine supplementation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cine display fluidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ACP documentation rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of ACP documentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incident cases of PAD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pain flare
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: triglycerides reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: HDL-C increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mention of mammography
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Performance of clinical breast examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in hip abductor strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Bone formation volume ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severe gingival swelling
Endpoint domain: Adverse events/effects
Primary endpoint: Chronotherapeutic compliance
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rhinoconjunctivitis quality of life scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Average rhinoconjunctivitis scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of well days
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Nursing time reduction
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Primary endpoint reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Stent thrombosis reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: GUSTO severe/moderate bleeding impact
Endpoint domain: Adverse events/effects
Primary endpoint: urinary 15-F2t-isoprostane
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of proven or probable invasive fungal infections (IFI)
Endpoint domain: Adverse events/effects
Primary endpoint: cumulative survival rates
Endpoint domain: Mortality/survival
Primary endpoint: Reduction in NEFA concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes